We report a case of reduced intensity stem cell transplantation (RI-SCT) using cells from a matched unrelated donor, for the treatment of pure red cell aplasia (PRCA). Owing to graft failure, a second infusion of stem cells from the same donor yielded complete donor engraftment within 3 months from the initial transplant. PRCA is a rare haematological disease characterised by anaemia with absence of red-cell precursors in the bone marrow, but normal granulopoiesis and megakaryopoiesis.
1 Acquired PRCA is associated with lymphoproliferative disorders, drugs, thymoma and autoimmune disorders. Infection, particularly human parvovirus B19, is associated with selflimited PRCA in healthy children and adults. 2 It has been described after allogeneic bone marrow transplantation from ABO incompatible donors. 3, 4 The pathogenic mechanisms of acquired PRCA generally relate to specific antibodies or direct T-cell lymphocyte toxicity to the red cell progenitors. Management of severe acquired or primary PRCA can be difficult. The mainstay of treatment includes immunosuppression with clinical responses of approximately 70%. 5 More intensive approaches such as allogeneic stem cell transplantation (AlloSCT) are required for more severely affected patients, but TRM limits its application. 6, 7 RI-SCT may confer benefits compared with conventional alloSCT 8 and this possibly supports its use for the management of severe PRCA in younger patients where iron overload represents an ongoing clinical problem.
A 28-year-old female patient initially presented with reduced haemoglobin, normal leucocyte and platelet numbers. Autoimmune screen, liver function tests, B12 and folate were normal and parvovirus serology was negative. A diagnosis of PRCA was confirmed by bone marrow aspirate and trephine. Cytogenetic analysis confirmed normal female karyotype. Screening test for Fanconi's anaemia and paroxysmal nocturnal haemoglobinuria were negative. Radiological imaging ruled out thymoma. Treatment modalities attempted over 11 years included transfusion support, steroids, cyclosporin, lowand high-dose erythropoietin, azathioprine, fludarabine and granulocyte colony-stimulating factor (G-CSF).
At the time of referral, the patient was 39 years old. Physical examination was normal, apart from signs of anaemia, and the Karnofsky Performance Score was 60-70%. Full blood count analysis demonstrated the following: Hb, 7.2 gm/dl, normal WCC and platelets. Bone marrow showed aplasia of the erythroid compartment and mild hyperplasia in the myeloid series. In vitro stem cell culture studies showed maturation arrest of the erythroid series. BFU colonies were responsive to in vitro erythropoietin leading to full maturation. The serum ferritin level was 3000 mg/l.
In view of the complications of continuous transfusion support, a bone marrow transplantation procedure was considered. Her age, satisfactory pre-transplant organ functions and negative virology screen lent support to the use of a RI-SCT from a fully matched unrelated male donor of the same blood group and with a negative virology screen. The conditioning regimen comprised CAMPATH In view of the slow haemoglobin recovery, erythropoeitin and folic acid were commenced with a poor response. A full blood group serology identified strongly to reacting anti-Kell antibodies. The donor antibody profile was K negative, k positive, R1, Duffy and Kidd positive. Plasma exchange (3-l) daily for 3 days followed by a total immunoglobulin fraction of 200 mg/kg resulted in a fall in the anti-K titres. Her transfusion requirements gradually reduced, and the Hb was maintained at 11 gm/dl by day 187 without transfusion or erythropoietin support. Hb, white cell, neutrophil and platelet counts are shown in Figure 1 . Full donor chimerism was observed within 3 months of the transplant procedure coincident with Hb recovery. The patient currently requires no red cell transfusion support. She has, however, developed grade 2 GVHD of the skin 6 months after transplant and thrombocytopenia, and is being treated with cyclosporin A.
There is limited and mixed experience of bone marrow transplantation in patients with PRCA. Muller et al 
